{"success":true,"data":{"pressRelease":{"id":"27737","rtpr_id":"nPn6RXlNda","ticker":"CODX","exchange":"NASDAQ","all_tickers":["CODX"],"title":"Co-Diagnostics Joint Venture CoMira Finalizes Lease Agreement for Manufacturing Facility in Saudi Arabia's Sudair Industrial City","author":"PR Newswire","published_at":"2026-05-08T13:00:00.796Z","article_body":"Co-Diagnostics Joint Venture CoMira Finalizes Lease Agreement for Manufacturing Facility in Saudi Arabia's Sudair Industrial City\n\nPR Newswire\n\nSALT LAKE CITY, May 8, 2026\n\nLease execution highlights transition from approval to development and\nadvances localized manufacturing strategy in the Kingdom of Saudi Arabia in\naccordance with Vision 2030\n\nSALT LAKE CITY, May 8, 2026 /PRNewswire/ -- Co-Diagnostics, Inc.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4684045-1&h=1225170074&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc.)\n(Nasdaq: CODX) (\"Co-Dx\" or \"the Company\"), a molecular diagnostics company\nwith a unique, patented platform for the development of molecular diagnostic\ntests, today announced that its joint venture, CoMira Diagnostics LLC\n(\"CoMira\"), has finalized a lease agreement for its planned manufacturing\nfacility in Sudair Industrial City in the Kingdom of Saudi Arabia (\"KSA\").\n\n(https://mma.prnewswire.com/media/1856437/Co_Diagnostics_New_Logo_v1.html)\n\nThe lease execution represents a key milestone as CoMira advances domestic\nmanufacturing capabilities within the KSA and follows the Company's previously\nannounced\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4684045-1&h=2521825983&u=https%3A%2F%2Fir.co-dx.com%2F2026-04-02-Co-Diagnostics-Joint-Venture-CoMira-Receives-Approval-for-Manufacturing-Facility-in-Kingdom-of-Saudi-Arabias-Sudair-Industrial-City&a=previously+announced)\napproval for an industrial land allocation in Sudair Industrial City by the\nSaudi Authority for Industrial Cities and Technology Zones (\"MODON\").\n\n\"Co-Dx continues to advance our CoMira joint venture, with today's lease\nfinalization marking an important milestone in expanding our presence in the\nKSA,\" said Dwight Egan, Chief Executive Officer of Co-Diagnostics. \"Executing\nthe lease moves us from planning into the execution phase of development and\nreflects ongoing progress in localizing our platform within Saudi Arabia. We\nbelieve this initiative supports the Kingdom's Vision 2030 goals related to\nhealthcare infrastructure, domestic manufacturing, and supply-chain\nresilience.\"\n\nThe lease covers an industrial facility of approximately 14,400 square feet in\nSudair Industrial City, one of Saudi Arabia's leading industrial hubs. The\nfacility is designated for approved manufacturing activities, including\ndiagnostic instruments, laboratory testing equipment, and medical consumables,\nand is intended to support CoMira's planned manufacturing activities related\nto the Co-Dx PCR platform* and other Co-Dx technology, subject to applicable\nregulatory approvals and operational requirements.\n\nThe turnkey nature of the facility is expected to support a more efficient\ntransition to operational readiness compared to traditional ground-up\ndevelopment, aligning with the Company's focus on capital-efficient expansion.\n\nIhssan Rjoob, CEO of CoMira Diagnostics, remarked \"Sudair Industrial City is\nintended to play a central role in Saudi Arabia's Vision 2030 initiative to\ndiversify the economy and expand local manufacturing capabilities. We believe\nthat establishing a presence within this industrial ecosystem aligns CoMira\nwith national priorities around healthcare localization and industrial\ndevelopment.\"\n\nCoMira is focused on establishing localized manufacturing and distribution\ncapabilities across Saudi Arabia and the broader Middle East and North Africa\n(MENA) region. The Company believes that domestic production of molecular\ndiagnostics within the Kingdom may offer strategic advantages, particularly in\ngovernment procurement processes that prioritize locally manufactured\nhealthcare solutions.\n\nIn addition, the Company believes that as relevant regulatory clearances are\nobtained by the U.S. FDA, the Co-Dx PCR platform may be introduced into the\nSaudi market through a more streamlined regulatory pathway compared to other\ninternational jurisdictions, potentially supporting earlier commercial\nactivity as the facility is developed.\n\nThis announcement represents the latest step in Co-Diagnostics' broader\nstrategy to deploy its platform globally through localized partnerships,\nincluding its CoSara joint venture in India, and reflects the Company's\ncontinued focus on scalable, capital-efficient international expansion.\n\n*The Co-Dx PCR platform (including the PCR Home(®), PCR Pro(®), mobile app,\nand all associated tests) is subject to review by the FDA and/or other\nregulatory bodies and is not yet available for sale.\n\nAbout Co-Diagnostics, Inc.:\nCo-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company\nthat develops, manufactures and markets state-of-the-art diagnostics\ntechnologies. The Company's technologies are utilized for tests that are\ndesigned using the detection and/or analysis of nucleic acid molecules (DNA or\nRNA). The Company also uses its proprietary technology to design specific\ntests for its Co-Dx PCR at-home and point-of-care platform (subject to\nregulatory review and not currently for sale) and to identify genetic markers\nfor use in applications other than infectious disease.\n\nForward-Looking Statements:\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Forward-looking\nstatements can be identified by words such as \"believes,\" \"expects,\"\n\"estimates,\" \"intends,\" \"may,\" \"plans,\" \"will,\" \"seeks,\" \"anticipates,\" and\nsimilar expressions, or the negative of these terms. Forward-looking\nstatements in this press release include, but are not limited to, statements\nregarding: (i) the planned development, timing, scope, and operationalization\nof a manufacturing facility by CoMira Diagnostics; (ii) the ability of such\nfacility to support manufacturing of molecular diagnostic instruments and\nassays; (iii) expectations regarding CoMira's positioning as an early domestic\nmanufacturer within the Kingdom of Saudi Arabia; (iv) the potential benefits\nof local manufacturing, including participation in government procurement\nprograms and contribution to Saudi Arabia's Vision 2030 objectives; and (v)\nthe Company's broader international expansion strategy across the Middle East\nand North Africa. These forward-looking statements are based on current\nexpectations, estimates, forecasts, and projections, as well as the beliefs\nand assumptions of management as of the date of this release. Such statements\nare subject to a number of risks and uncertainties, including, without\nlimitation: risks associated with satisfying infrastructure requirements and\nother conditions precedent; risks related to the design, financing,\nconstruction, and timely completion of the contemplated manufacturing\nfacility; risks associated with operating through a joint venture, including\ngovernance, funding, and partner-related risks; risks related to obtaining and\nmaintaining required regulatory approvals in the Kingdom of Saudi Arabia and\nother jurisdictions; risks that anticipated benefits of localization and\nparticipation in government procurement programs are not realized;\nuncertainties associated with market acceptance and adoption of the Company's\nproducts; competitive dynamics in the global molecular diagnostics market;\nexecution risks associated with international expansion; and general economic,\ngeopolitical, and public health conditions in the regions in which the Company\noperates or intends to operate. Actual results may differ materially from\nthose expressed or implied in these forward-looking statements. Readers are\ncautioned not to place undue reliance on forward-looking statements. A further\ndescription of risks and uncertainties can be found in the Company's Annual\nReport on Form 10-K filed with the Securities and Exchange Commission on March\n31, 2026, and in its other filings with the SEC. The Company undertakes no\nobligation to update any forward-looking statements to reflect events or\ncircumstances after the date of this press release, except as required by\napplicable law.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/co-diagnostics-joint-venture-comira-finalizes-lease-agreement-for-manufacturing-facility-in-saudi-arabias-sudair-industrial-city-302766568.html\n(https://www.prnewswire.com/news-releases/co-diagnostics-joint-venture-comira-finalizes-lease-agreement-for-manufacturing-facility-in-saudi-arabias-sudair-industrial-city-302766568.html)\n\nSOURCE Co-Diagnostics\n\n\n\nCompany Contact: Andrew Benson, Head of Investor Relations, +1 801.438.1036, investors@codiagnostics.com; Investor Contact: Valter Pinto, Managing Director, KCSA Strategic Communications, +1 212.896.1254, CODX@KCSA.com; Media Contact: Jennifer Webb, ColtrinMethod PR, jcoltrin@coltrinmethodpr.com\n\nPhoto: \nhttps://mma.prnewswire.com/media/1856437/Co_Diagnostics_New_Logo_v1.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn6RXlNda","title":"Co-Diagnostics Joint Venture CoMira Finalizes Lease Agreement for Manufacturing Facility in Saudi Arabia's Sudair Industrial City","author":"PR Newswire","ticker":"CODX","created":"2026-05-08T13:00:00.796Z","tickers":["CODX"],"exchange":"NASDAQ","article_body":"Co-Diagnostics Joint Venture CoMira Finalizes Lease Agreement for Manufacturing Facility in Saudi Arabia's Sudair Industrial City\n\nPR Newswire\n\nSALT LAKE CITY, May 8, 2026\n\nLease execution highlights transition from approval to development and\nadvances localized manufacturing strategy in the Kingdom of Saudi Arabia in\naccordance with Vision 2030\n\nSALT LAKE CITY, May 8, 2026 /PRNewswire/ -- Co-Diagnostics, Inc.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4684045-1&h=1225170074&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc.)\n(Nasdaq: CODX) (\"Co-Dx\" or \"the Company\"), a molecular diagnostics company\nwith a unique, patented platform for the development of molecular diagnostic\ntests, today announced that its joint venture, CoMira Diagnostics LLC\n(\"CoMira\"), has finalized a lease agreement for its planned manufacturing\nfacility in Sudair Industrial City in the Kingdom of Saudi Arabia (\"KSA\").\n\n(https://mma.prnewswire.com/media/1856437/Co_Diagnostics_New_Logo_v1.html)\n\nThe lease execution represents a key milestone as CoMira advances domestic\nmanufacturing capabilities within the KSA and follows the Company's previously\nannounced\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4684045-1&h=2521825983&u=https%3A%2F%2Fir.co-dx.com%2F2026-04-02-Co-Diagnostics-Joint-Venture-CoMira-Receives-Approval-for-Manufacturing-Facility-in-Kingdom-of-Saudi-Arabias-Sudair-Industrial-City&a=previously+announced)\napproval for an industrial land allocation in Sudair Industrial City by the\nSaudi Authority for Industrial Cities and Technology Zones (\"MODON\").\n\n\"Co-Dx continues to advance our CoMira joint venture, with today's lease\nfinalization marking an important milestone in expanding our presence in the\nKSA,\" said Dwight Egan, Chief Executive Officer of Co-Diagnostics. \"Executing\nthe lease moves us from planning into the execution phase of development and\nreflects ongoing progress in localizing our platform within Saudi Arabia. We\nbelieve this initiative supports the Kingdom's Vision 2030 goals related to\nhealthcare infrastructure, domestic manufacturing, and supply-chain\nresilience.\"\n\nThe lease covers an industrial facility of approximately 14,400 square feet in\nSudair Industrial City, one of Saudi Arabia's leading industrial hubs. The\nfacility is designated for approved manufacturing activities, including\ndiagnostic instruments, laboratory testing equipment, and medical consumables,\nand is intended to support CoMira's planned manufacturing activities related\nto the Co-Dx PCR platform* and other Co-Dx technology, subject to applicable\nregulatory approvals and operational requirements.\n\nThe turnkey nature of the facility is expected to support a more efficient\ntransition to operational readiness compared to traditional ground-up\ndevelopment, aligning with the Company's focus on capital-efficient expansion.\n\nIhssan Rjoob, CEO of CoMira Diagnostics, remarked \"Sudair Industrial City is\nintended to play a central role in Saudi Arabia's Vision 2030 initiative to\ndiversify the economy and expand local manufacturing capabilities. We believe\nthat establishing a presence within this industrial ecosystem aligns CoMira\nwith national priorities around healthcare localization and industrial\ndevelopment.\"\n\nCoMira is focused on establishing localized manufacturing and distribution\ncapabilities across Saudi Arabia and the broader Middle East and North Africa\n(MENA) region. The Company believes that domestic production of molecular\ndiagnostics within the Kingdom may offer strategic advantages, particularly in\ngovernment procurement processes that prioritize locally manufactured\nhealthcare solutions.\n\nIn addition, the Company believes that as relevant regulatory clearances are\nobtained by the U.S. FDA, the Co-Dx PCR platform may be introduced into the\nSaudi market through a more streamlined regulatory pathway compared to other\ninternational jurisdictions, potentially supporting earlier commercial\nactivity as the facility is developed.\n\nThis announcement represents the latest step in Co-Diagnostics' broader\nstrategy to deploy its platform globally through localized partnerships,\nincluding its CoSara joint venture in India, and reflects the Company's\ncontinued focus on scalable, capital-efficient international expansion.\n\n*The Co-Dx PCR platform (including the PCR Home(®), PCR Pro(®), mobile app,\nand all associated tests) is subject to review by the FDA and/or other\nregulatory bodies and is not yet available for sale.\n\nAbout Co-Diagnostics, Inc.:\nCo-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company\nthat develops, manufactures and markets state-of-the-art diagnostics\ntechnologies. The Company's technologies are utilized for tests that are\ndesigned using the detection and/or analysis of nucleic acid molecules (DNA or\nRNA). The Company also uses its proprietary technology to design specific\ntests for its Co-Dx PCR at-home and point-of-care platform (subject to\nregulatory review and not currently for sale) and to identify genetic markers\nfor use in applications other than infectious disease.\n\nForward-Looking Statements:\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Forward-looking\nstatements can be identified by words such as \"believes,\" \"expects,\"\n\"estimates,\" \"intends,\" \"may,\" \"plans,\" \"will,\" \"seeks,\" \"anticipates,\" and\nsimilar expressions, or the negative of these terms. Forward-looking\nstatements in this press release include, but are not limited to, statements\nregarding: (i) the planned development, timing, scope, and operationalization\nof a manufacturing facility by CoMira Diagnostics; (ii) the ability of such\nfacility to support manufacturing of molecular diagnostic instruments and\nassays; (iii) expectations regarding CoMira's positioning as an early domestic\nmanufacturer within the Kingdom of Saudi Arabia; (iv) the potential benefits\nof local manufacturing, including participation in government procurement\nprograms and contribution to Saudi Arabia's Vision 2030 objectives; and (v)\nthe Company's broader international expansion strategy across the Middle East\nand North Africa. These forward-looking statements are based on current\nexpectations, estimates, forecasts, and projections, as well as the beliefs\nand assumptions of management as of the date of this release. Such statements\nare subject to a number of risks and uncertainties, including, without\nlimitation: risks associated with satisfying infrastructure requirements and\nother conditions precedent; risks related to the design, financing,\nconstruction, and timely completion of the contemplated manufacturing\nfacility; risks associated with operating through a joint venture, including\ngovernance, funding, and partner-related risks; risks related to obtaining and\nmaintaining required regulatory approvals in the Kingdom of Saudi Arabia and\nother jurisdictions; risks that anticipated benefits of localization and\nparticipation in government procurement programs are not realized;\nuncertainties associated with market acceptance and adoption of the Company's\nproducts; competitive dynamics in the global molecular diagnostics market;\nexecution risks associated with international expansion; and general economic,\ngeopolitical, and public health conditions in the regions in which the Company\noperates or intends to operate. Actual results may differ materially from\nthose expressed or implied in these forward-looking statements. Readers are\ncautioned not to place undue reliance on forward-looking statements. A further\ndescription of risks and uncertainties can be found in the Company's Annual\nReport on Form 10-K filed with the Securities and Exchange Commission on March\n31, 2026, and in its other filings with the SEC. The Company undertakes no\nobligation to update any forward-looking statements to reflect events or\ncircumstances after the date of this press release, except as required by\napplicable law.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/co-diagnostics-joint-venture-comira-finalizes-lease-agreement-for-manufacturing-facility-in-saudi-arabias-sudair-industrial-city-302766568.html\n(https://www.prnewswire.com/news-releases/co-diagnostics-joint-venture-comira-finalizes-lease-agreement-for-manufacturing-facility-in-saudi-arabias-sudair-industrial-city-302766568.html)\n\nSOURCE Co-Diagnostics\n\n\n\nCompany Contact: Andrew Benson, Head of Investor Relations, +1 801.438.1036, investors@codiagnostics.com; Investor Contact: Valter Pinto, Managing Director, KCSA Strategic Communications, +1 212.896.1254, CODX@KCSA.com; Media Contact: Jennifer Webb, ColtrinMethod PR, jcoltrin@coltrinmethodpr.com\n\nPhoto: \nhttps://mma.prnewswire.com/media/1856437/Co_Diagnostics_New_Logo_v1.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-08T13:00:00.935610614Z","server_sent_at_ms":1778245200935},"received_at":"2026-05-08T13:00:01.095Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}